That is called another mngnt bungle, Everyone in pharma knew from AACR and publications that I/o drugs were next and getting BTD and approvals. Even Pphm knew and jumped on the bandwagon changing Bavi to an I/o drug.
That is the reason a r&d biotech partners....even if mngnt was too ignorant or greedy to know the io landscape, bp would have.
Market Data 
Markets 
AI
